Last reviewed · How we verify
Naval Medical Research Center — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tafenoquine prophylaxis | Tafenoquine prophylaxis | marketed | 8-aminoquinoline antimalarial | Plasmodium mitochondrial electron transport chain | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- London School of Hygiene and Tropical Medicine · 1 shared drug class
- Menzies School of Health Research · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Naval Medical Research Center:
- Naval Medical Research Center pipeline updates — RSS
- Naval Medical Research Center pipeline updates — Atom
- Naval Medical Research Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Naval Medical Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/naval-medical-research-center. Accessed 2026-05-17.